Expanded Programme on Immunization (EPI)

Size: px
Start display at page:

Download "Expanded Programme on Immunization (EPI)"

Transcription

1 Timor-Leste 217 Expanded Programme on Immunization (EPI) FACT SHEET

2 Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles containing vaccine AFP Acute flaccid paralysis MICS Multiple indicator cluster survey BCG Bacillus Calmette-Guérin vaccine MMR Measles mumps rubella vaccine CES Coverage evaluation survey MNT Maternal and neonatal tetanus cmyp Comprehensive multi-year plan MR Measles rubella vaccine CRS Congenital rubella syndrome NCIP National committee on immunization practices DHS Demographic health survey NID National immunization day DT Diphtheria tetanus toxoid, pediatric NTAGI National technical advisory group on immunization DTP Diphtheria tetanus pertussis vaccine NPEV Non-polio enterovirus DTP-Hib-HepB Pentavalent vaccine NT Neonatal tetanus DTP-Hib-HepB3 3rd dose pentavalent vaccine OPV Oral poliovirus vaccine EPI Expanded programme on immunization bopv Bivalent OPV GDP Gross domestic product topv Trivalent OPV HCW Health care worker PCV Pneumococcal conjugate vaccine HepB Hepatitis B vaccine SEAR WHO South-East Asia Region Hib Haemophilus influenzae type b SIA Supplementary immunization activities HPV Human papilloma virus SNID Subnational immunization day IgM Immunoglobulin M Td Tetanus diphtheria toxoid; older children, adults IPV Inactivated poliovirus vaccine TT Tetanus toxoid JE Japanese encephalitis TT2+ 2 or more doses TT JE_Live-Atd JE live attenuated vaccine VDPV Vaccine derived poliovirus JRF WHO UNICEF joint reporting form VPD Vaccine preventable diseases LB Live birth WCBA Women of child bearing age M Measles WPV Wild poliovirus

3 Contents Impact of routine immunization EPI history 5 Basic information 216 Table 1 5 Immunization schedule 216 Table 2 5 National immunization coverage Figure 1 6 Immunization system highlights Table 3 6 DTP3 coverage, diphtheria and pertussis cases Figure 2 7 Reported cases of vaccine preventable diseases Table 4 7 DTP-Hib-HepB3 coverage by district 215 Figure 3 7 DTP-Hib-HepB3 coverage by district 216 Figure 4 7 Maternal and neonatal tetanus elimination is sustained TT2+ coverage and NT cases Figure 5 8 Polio-free status is maintained Page No. Page No. Page No. AFP surveillance indicators Table 5 9 Non-polio AFP rate by district 215 Figure 6 9 Non-polio AFP rate by district 216 Figure 7 9 Adequate stool specimen collection percentage by district 215 Figure 8 1 Adequate stool specimen collection percentage by district 216 Figure 9 1 OPV supplementary immunization activities Table 6 1 Towards measles elimination and rubella/congenital rubella syndrome control Page No. MCV1 and MCV2 coverage, measles and rubella cases, Figure 1 11 MCV supplementary immunization activities Table 7 11 MCV1 coverage by district 215 Figure MCV1 coverage by district 216 Figure MCV2 coverage by district 215 Figure MCV1 coverage by district 216 Figure Immunity against measles immunity profile by age in 216 Figure Subnational risk assessment for measles and rubella Figure Sporadic and outbreak associated measles cases by month Figure Immunization status of confirmed (laboratory and Epi linked) measles outbreak associated cases by age Figure Quality of field and laboratory surveillance for measles and rubella Table 8 14 Performance of laboratory surveillance Table 9 14 WHO supported laboratory network for VPD surveillance Figure 19 15

4 WHO South-East Asia Region Timor-Leste: district level map Disclaimer: The boundaries and names shown and the designations used on all the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area of its authorities, or concerning the delimitation of its frontiers or boundaries. 4

5 Impact of routine immunization Table 1: Basic information EPI history EPI started in 1978 EPI re-structured in March 2 DTP-HepB vaccine introduced in 27 DTP-Hib-HepB) vaccine introduced in 212 MR vaccine introduced in Feb 216 Second dose of MR introduced in Feb 216 HepB birth dose introduced in Feb 216 Total population 1,231,262 Live births 35,426 Children <1 year 33,548 Children <5 years 176,377 Children <15 years 493,795 Pregnant women 38,969 WCBA (15-49 years) 154,65 Neonatal mortality rate 22.3 (per 1, LB) Infant mortality rate 44.7 (per 1, LB) Under-five mortality rate 52.6 (per 1, LB) Maternal mortality ratio 215 (per 1, LB) 1 SEAR annual EPI reporting form, 216 and WHO, World Health Statistics 216 Division/Province/State/Region - Municipalities 13 Postos/Sub-district 65 Sucos/Village 442 Population density (per sq. km) 71 Population living in urban areas 32% Population using improved drinking-water sources 7% Population using improved sanitation 39% Total expenditure on health as % of GDP 1.4% Births attended by skilled health personnel 21% Neonates protected at birth against NT 81% DPT/DT vaccine (booster dose) introduced in Feb 216 IPV introduced in Feb 216 topv to bopv switched on 18 April 216. Source: cmyp and EPI/MOH Table 2: Immunization schedule, 216 Vaccine Age of administration BCG Birth OPV Birth, 6 weeks, 1 weeks and 14 weeks DTP-Hib-HepB 6 weeks, 1 weeks and 14 weeks MR 9 months and 18 months TT Females 15 to 49 years (1st pregnancy contact, +1 month, +6 months, +1 year, +1 year) Vitamin A 6 to 36 months (with 6 months interval) IPV 14 weeks DT 6 years Source: WHO/UNICEF JRF, 216 5

6 Figure 1: National immunization coverage, % Coverage BCG DTP OPV MCV Source: WHO/UNICEF estimates of national immunization coverage, July 217 revision Table 3: Immunization system highlights cmyp for immunization NTAGI fully functional Spending on vaccines financed by the government 76% Spending on routine immunization programme financed by the government 39% Updated micro-plans that include activities to improve immunization coverage 13 districts (1%) National policy for health care waste management including waste from immunization activities National system to monitor AEFI Most recent EPI CES in place in place EPI CES Dili municipality and 12 other municipalities 215 >8% coverage for DTP-Hib-HepB3 13 districts (1%) >9% coverage for MCV1 7 districts (54%) >1% drop-out rate for DTP-Hib-HepB1 to DTP-Hib-HepB3 no district Source: WHO/UNICEF JRF, 216 6

7 Figure 2: DTP3 coverage 1, diphtheria and pertussis cases 2, DTP-Hib-HepB3 coverage by district 25 8 No. of cases % Coverage Figure 3: Year Source: SEAR annual EPI reporting form, 215 (administrative data) Diphtheria Cases Pertussis Cases DTP3 Coverage 1 WHO/UNICEF estimates of national immunization coverage, July 217 revision 2 WHO vaccine-preventable diseases: monitoring system 216 Figure 4: 216 Table 4: Reported cases of vaccine preventable diseases, Year Polio Diphtheria Pertussis NT (% of all tetanus) Measles Rubella Mumps JE CRS (67%) (4%) 16 8 Source: SEAR annual EPI reporting form, 216 (administrative data) (9%) 4 ND 5 ND ND Source: WHO/UNICEF JRF ( ) ND=No data <7% 7% - 79% 8% - 89% > 9% 7

8 Maternal and neonatal tetanus elimination is sustained Figure 5: TT2+ coverage 1 and NT cases 2, MNT elimination in No. of cases % Coverage Year WHO/Timor-Leste/S Singh 1 WHO/UNICEF JRF, Country official estimates, WHO vaccine-preventable diseases: monitoring system 216 NT Cases TT2+ Coverage 8

9 Polio-free status is maintained Table 5: AFP surveillance performance indicators, Indicator AFP cases Wild poliovirus confirmed cases Compatible cases Non-polio AFP rate Adequate stool specimen collection percentage 2 4% 2% 67% 5 Total stool samples collected % NPEV isolation - % Timeliness of primary result reported Number of discarded AFP cases per 1, children under 15 years of age. 2 Percent with 2 specimens, at least 24 hours apart and within 14 days of paralysis onset. 3 Results reported within 14 days of sample received at laboratory. Non-polio AFP rate by district Figure 6: 215 Figure 7: 216 WHO/Timor-Leste/S Singh < >2 No non-polio AFP case 9

10 Adequate stool specimen collection % by district Figure 8: 215 Figure 9: 216 <6% 6% - 79% >8% No AFP Table 6: OPV SIAs Year Vaccine Geographic coverage Target age Target population Coverage (%) Round 1 Round 2 Round 1 Round 2 25 OPV NID <5 years 177, * OPV NID <5 years 522, * During MR vaccination campaign. Source: WHO/UNICEF JRF 1

11 Towards measles elimination and rubella/crs control Figure 1: MCV1 and MCV2 coverage 1, measles and rubella cases 2, Table 7: MCV SIAs Year Antigen Geographic coverage Target group Target Coverage % M nationwide 9 to 59 months 128, No. of cases No data % Coverage 26 M nationwide 29 M nationwide 211 M nationwide 6 months to 14 years 9 to 59 months 6 months to 14 years 39, , , Year Measles Cases Rubella MCV1 Coverage MCV2 Coverage 1 WHO/UNICEF estimates of national immunization coverage, July 217 revision 2 WHO vaccine-preventable diseases: monitoring system MR nationwide 6 months to 14 years 51, Source: WHO/UNICEF JRF, (multiple years) 11

12 MCV1 coverage by district Figure 15: Immunity against measles - immunity profile by age in 216* 1% Figure 11: 215 Source: SEAR annual EPI reporting form, 215 (administrative data) Percent of population 8% 6% 4% 2% Figure 12: 216 MCV2 coverage by district Source: SEAR annual EPI reporting form, 216 (administrative data) % Age (in years) Protected by maternal antibodies Protected by routine vaccination with 1st dose Protected by routine vaccination with 2nd dose Protected by SIAs Immune due to past infection Susceptible * Modeled using MSP tool ver 2 assuming the schedule and MCV coverage remain unchanged in 216. Figure 16: Sub-national risk assessment -measles and rubella Figure 13: 215 Source: SEAR annual EPI reporting form, 215 (administrative data) Figure 14 : 216 Very high risk High risk Medium risk Low risk Not available Source: SEAR annual EPI reporting form, 216 (administrative data) <8% 8% - 89% 9% - 94% >95% 12 Source: developed using WHO risk assessment tool based on JRF & ARF data base

13 Figure 17: Sporadic and outbreak associated measles cases* by month No of cases Sporadic measles Outbreak associated measles 1 5 Feb-12 Mar-12 Apr-12 May-12 Jun-12 Jul-12 Aug-12 Sep-12 Oct-12 Nov-12 Dec-12 Jan-13 Feb-13 Mar-13 Apr-13 May-13 Jun-13 Jul-13 Aug-13 Sep-13 Oct-13 Nov-13 Dec-13 Jan-14 Feb-14 Mar-14 Apr-14 May-14 Jun-14 Jul-14 Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 *Includes laboratory confirmed and epidemiologically linked cases Source: SEAR Monthly VPD reports Figure 18: Immunization status of confirmed (laboratory and EPI linked) measles outbreak associated cases, by age, WHO/Timor-Leste/S Singh 1-4 years 5-9 years 1-14 years > 15 years < 1 year 1-4 years 5-9 years 1-14 years > 15 years < 1 year 1-4 years 5-9 years 1-14 years > 15 years < 1 year 1-4 years 5-9 years 1-14 years > 15 years < 1 year 1-4 years 5-9 years 1-14 years > 15 years < 1 year 1-4 years 5-9 years 1-14 years > 15 years Immunized Not immunized/ unknown Source: SEAR annual EPI reporting form ( ) 13

14 Table 8: Surveillance performance indicators for measles and rubella, Case classification (number) Indicators Year No. of suspected measles Lab-confirmed Measles EPI-linked Clinically-confirmed Lab-confirmed Rubella EPI-linked Discarded non-measles nonrubella cases Annual incidence of confirmed measles cases per million total population Annual incidence of confirmed rubella cases per million total population Proportion of all suspected measles and rubella cases that have had an adequate investigation initiated within 48 hours of notification Discarded non-measles nonrubella incidence per 1, total population Proportion of districts reporting at least two discarded non-measles nonrubella cases per 1, total population Proportion of sub-national surveillance units reporting to the national level on time Target - - 8% 2 8% 8% ND 1 Source: SEAR annual EPI reporting form ( ) ND=No data Table 9: Performance of laboratory surveillance, Year Serum specimen collected from suspected measles cases Serum specimen received in laboratory within 5 days of collection Specimen positive for measles IgM Specimen positive for rubella IgM % Results within 4 days of receipt % Positive cases tested for viral detection No (%) No (%) No. % No. % Measles Rubella (46%) 13 (1%) (25%) 1 (1%) (91%) 43 (1%) (71%) 34 (1%) (9%) 119 (1%) Source: SEAR annual EPI reporting form ( ) ND=No data Genotypes detected 14

15 Figure 19: WHO supported laboratory network for VPD surveillance National Health Laboratory, Dili National measles and rubella laboratory National Japanese encephalitis laboratory 15

16 For contact or feedback: Expanded Programme on Immunization Ministry of Health, Dilli, Timor-Leste Tel: , Fax: Immunization and Vaccine Development (IVD) WHO-SEARO, IP Estate, MG Marg, New Delhi 112, India Tel: , Fax:

Expanded Programme on Immunization (EPI)

Expanded Programme on Immunization (EPI) Indonesia 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles

More information

Expanded Programme on Immunization (EPI)

Expanded Programme on Immunization (EPI) Sri Lanka 217 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles

More information

Expanded Programme on Immunization (EPI)

Expanded Programme on Immunization (EPI) Bhutan 2017 Expanded Programme on Immunization (EPI) FACT SHEET Acronyms AD Auto disable MCV1 First dose measles containing vaccine AEFI Adverse events following immunization MCV2 Second dose measles containing

More information

Table 1: Basic information (per 1,000 LB) 42.4 (per 1,000 LB) 49.7 (per 1,000 LB) 215 (per 100,000 LB)

Table 1: Basic information (per 1,000 LB) 42.4 (per 1,000 LB) 49.7 (per 1,000 LB) 215 (per 100,000 LB) EPI history EPI started in 978 EPI re-structured in March 000 DTP-HepB vaccine introduced in 007 DTP-Hib-HepB)vaccine introduced in 0 MR vaccine introduced in Feb 06 Second dose of MR introduced in Feb

More information

Total population 1,212,110. Live births (LB) 43,924. Children <1 year 40,351. Children <5 years 192,340. Children <15 years 510,594

Total population 1,212,110. Live births (LB) 43,924. Children <1 year 40,351. Children <5 years 192,340. Children <15 years 510,594 Draft version for the SEAR-ITAG 5-9 June 5 All data provisional as of May 5 Timor Leste 4 Immunization system highlights There is a comprehensive multi-year plan (cmyp) for immunization covering 3-5. 8%

More information

Total population 24,759,000. Live births (LB) 342,458. Children <1 year 337,950. Children <5 years 1,698,664. Children <15 years 5,233,093

Total population 24,759,000. Live births (LB) 342,458. Children <1 year 337,950. Children <5 years 1,698,664. Children <15 years 5,233,093 DPR Korea 4 Immunization system highlights There is a comprehensive multiyear plan (cmyp) for immunization covering -5. A standing national technical advisory group on immunization (NTAGI) with formal

More information

Table 1: Basic information Total population 25,030, (per 100,000 LB) Division/Province/State/Region 11. District 210

Table 1: Basic information Total population 25,030, (per 100,000 LB) Division/Province/State/Region 11. District 210 EPI history EPI launched in 980 HepB vaccine introduced in 003 AD syringes introduced in 003 HepB birth dose introduced in 004 DTP-HepB vaccine introduced in 006 MCV introduced in 008 DTP-Hib-HepB vaccine

More information

Table 1: Basic information 2017

Table 1: Basic information 2017 EPI history EPI launched in 978 OPV and MCV introduced in 987 AD syringes introduced in 00 HepB vaccine introduced in 003 MCV introduced partially in 008 and made available nationwide in 0 DTP-Hib-HepB

More information

Total population 20,675,000. Live births (LB) 349,715. Children <1 year 346,253. Children <5 years 1,778,050. Children <15 years 5,210,100

Total population 20,675,000. Live births (LB) 349,715. Children <1 year 346,253. Children <5 years 1,778,050. Children <15 years 5,210,100 Sri Lanka 4 Immunization system highlights There is a comprehensive multi-year plan (cmyp) for immunization system strengthening covering -6. A national policy on immunization has been developed. A standing

More information

Total population 1,265,308,000. Live births (LB) 27,016,000. Children <1 year 25,928,200. Children <5 years 23,818,000. Children <15 years 25,639,000

Total population 1,265,308,000. Live births (LB) 27,016,000. Children <1 year 25,928,200. Children <5 years 23,818,000. Children <15 years 25,639,000 India 4 Immunization system highlights There is a comprehensive multiyear plan (cmyp) for immunization covering 3-7. National technical advisory group on immunization (NTAGI) exists and formal written

More information

Table 1: Basic information ,000, (per 1,000 LB) 34.6 (per 1,000 LB) 174 (per 100,000 LB) District 712.

Table 1: Basic information ,000, (per 1,000 LB) 34.6 (per 1,000 LB) 174 (per 100,000 LB) District 712. EPI history EPI launched in 978 with DPT, OPV, BCG and typhoid vaccines TT immunization of pregnant women introduced in 983 MCV introduced in 985 HepB piloted in 00 and made universal in 0 MCV introduced

More information

Immunization and Vaccine Development (IVD) SEARO

Immunization and Vaccine Development (IVD) SEARO Monthly Vaccine Preventable Disease and Immunization Update Published: January 03, 2018 Immunization and Vaccine Development (IVD) SEARO Protecting People from Vaccine Preventable Diseases Last wild poliovirus

More information

Monthly Vaccine Preventable Disease and Immunization Update Published: May 11, 2018 Immunization and Vaccine Development (IVD) SEARO

Monthly Vaccine Preventable Disease and Immunization Update Published: May 11, 2018 Immunization and Vaccine Development (IVD) SEARO Monthly Vaccine Preventable Disease and Immunization Update Published: May 11, 2018 Immunization and Vaccine Development (IVD) SEARO Protecting People from Vaccine Preventable Diseases Last wild poliovirus

More information

Monthly Vaccine Preventable Disease and Immunization Update Published: March 10, 2015 Immunization and Vaccine Development (IVD) SEARO

Monthly Vaccine Preventable Disease and Immunization Update Published: March 10, 2015 Immunization and Vaccine Development (IVD) SEARO Monthly Vaccine Preventable Disease and Immunization Update Published: March 10, 2015 Immunization and Vaccine Development (IVD) SEARO Protecting People from Vaccine Preventable Diseases Last wild poliovirus

More information

Addendum to IPV Introduction Guidelines based on Recommendations of India Expert Advisory Group (IEAG)

Addendum to IPV Introduction Guidelines based on Recommendations of India Expert Advisory Group (IEAG) Addendum to IPV Introduction Guidelines based on Recommendations of India Expert Advisory Group (IEAG) Background India was certified polio-free along with 10 other countries of WHO South-East Asia Region

More information

Immunization and Vaccine Development (IVD) SEARO

Immunization and Vaccine Development (IVD) SEARO VPD Update for Week 33, 2014 Data as of 18 August 2014 Immunization and Vaccine Development (IVD) SEARO Protecting People from Vaccine Preventable Diseases Last wild poliovirus case by type, SEAR WPV Type

More information

Afghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision

Afghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision Afghanistan: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data

More information

Selected vaccine introduction status into routine immunization

Selected vaccine introduction status into routine immunization Selected introduction status into routine infant immunization worldwide, 2003 This report summarizes the current status of national immunization schedules in 2003, as reported by Member States in the /UNICEF

More information

Measles and Rubella Fact Sheet SEAR #

Measles and Rubella Fact Sheet SEAR # and Fact Sheet SEAR 8-9 Table : South-East Asia Regional (SEAR) Strategic Plan 7- Goal: To reduce the number of measles deaths by 9 in relative to estimates. Objectives: Achieve at least 9 national Containing

More information

Joint National/International Expanded Programme on Immunization and Vaccine Preventable Disease Surveillance Review

Joint National/International Expanded Programme on Immunization and Vaccine Preventable Disease Surveillance Review SEA-Immun-97 Distribution: General Joint National/International Expanded Programme on Immunization and Vaccine Preventable Disease Surveillance Review Democratic Socialist Republic of 16 26 October 2015

More information

The Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007

The Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007 History & Future of the Expanded Programme on Immunization Supplier Meeting, Copenhagen, 3-4 April 2008 Dr Osman David Mansoor Senior Adviser EPI (New Vaccines) UNICEF New York The Gates Challenge If we

More information

Pakistan: WHO and UNICEF estimates of immunization coverage: 2017 revision

Pakistan: WHO and UNICEF estimates of immunization coverage: 2017 revision Pakistan: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data received

More information

Nigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision

Nigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision Nigeria: WHO and UNICEF estimates of immunization coverage: 2017 revision July 7, 2018; page 1 WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2019 data received

More information

OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE

OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE OVERVIEW OF THE NATIONAL CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE Dr Tiong Wei Wei, MD, MPH Senior Assistant Director Policy and Control Branch, Communicable Diseases Division Ministry of Health 9

More information

Immunization Update & focus on meningococcal vaccine PART 1

Immunization Update & focus on meningococcal vaccine PART 1 Immunization Update & focus on meningococcal vaccine PART 1 Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases University of Cape Town www.vacfa.uct.ac.za Disclosures Received

More information

National HPV Vaccine Coverage, WHO- UNICEF Joint Reporting Form

National HPV Vaccine Coverage, WHO- UNICEF Joint Reporting Form resource from : Evaluating HPV vaccination pilots: practical experience from path publication title National HPV Vaccine Coverage, WHO- UNICEF Joint Reporting Form publisher WHO/UNICEF publication date

More information

Evaluating Immunisation Dropout Rates in Eight Hard to Reach Unions of Maulvibazar District, Bangladesh

Evaluating Immunisation Dropout Rates in Eight Hard to Reach Unions of Maulvibazar District, Bangladesh International Journal of Immunology 2017; 5(1): 5-10 http://www.sciencepublishinggroup.com/j/iji doi: 10.11648/j.iji.20170501.12 ISSN: 2329-177X (Print); ISSN: 2329-1753 (Online) Evaluating Immunisation

More information

Global and National Trends in Vaccine Preventable Diseases. Dr Brenda Corcoran National Immunisation Office.

Global and National Trends in Vaccine Preventable Diseases. Dr Brenda Corcoran National Immunisation Office. Global and National Trends in Vaccine Preventable Diseases Dr Brenda Corcoran National Immunisation Office Global mortality 2008 Children under 5 years of age 1.5 million deaths due to vaccine preventable

More information

Immunizations are among the most cost effective and widely used public health interventions.

Immunizations are among the most cost effective and widely used public health interventions. Focused Issue of This Month Recommended by the Korean Pediatric Society, 2008 Hoan Jong Lee, MD Department of Pediatrics, Seoul National University College of Medicine E mail : hoanlee@snu.ac.kr J Korean

More information

South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) Meeting Report

South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) Meeting Report The eighth meeting of the World Health Organization's South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) was held from 13 to 16 June 2017 in New Delhi, India. SEAR-ITAG is a technical

More information

Requirements for new trials to examine offtarget. vaccination. Workshop on: Off-target (heterologous/non-specific) effects of vaccination.

Requirements for new trials to examine offtarget. vaccination. Workshop on: Off-target (heterologous/non-specific) effects of vaccination. Requirements for new trials to examine offtarget effects of vaccination Workshop on: Off-target (heterologous/non-specific) effects of vaccination Les Pensieres Jun 8-10, 2015 PEM Fine London School of

More information

WHO Library Cataloguing-in-Publication Data. World health statistics 2011.

WHO Library Cataloguing-in-Publication Data. World health statistics 2011. WORLD HEALTH STATISTICS 2011 WHO Library Cataloguing-in-Publication Data World health statistics 2011. 1.Health status indicators. 2.World health. 3.Health services - statistics. 4.Mortality. 5.Morbidity.

More information

The State of Measles and Rubella in the WHO European Region

The State of Measles and Rubella in the WHO European Region The State of Measles and Rubella in the WHO European Region Mark Muscat Vaccine-preventable Diseases and Immunization Rome, Italy, 16-17 June 2016 All six WHO Regions have measles elimination goals 2 Annual

More information

Task Force on Immunization (TFI) in Africa 14 th Annual Meeting. And. Africa Regional Inter-Agency Coordination Committee (ARICC) 13 th Annual Meeting

Task Force on Immunization (TFI) in Africa 14 th Annual Meeting. And. Africa Regional Inter-Agency Coordination Committee (ARICC) 13 th Annual Meeting Task Force on Immunization (TFI) in Africa 14 th Annual Meeting And Africa Regional Inter-Agency Coordination Committee (ARICC) 13 th Annual Meeting Meeting Report Maputo, Mozambique 27 29 November 2006

More information

GAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012

GAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012 GAVI partners Forum, Dar es Salaam, Tanzania December 5-7, 2012 ADRESSING CHALLENGES TO SUSTAINABLE NEW VACCINE INTRODUCTION: PERSPECTIVE FROM MONGOLIA N.UDVAL, MD, Sc D MINISTER OF HEALTH MONGOLIA CONTENT

More information

Polio Eradication in India. Dr Sunil Bahl Deputy Project Manager WHO Country Office for India 28 October 2014

Polio Eradication in India. Dr Sunil Bahl Deputy Project Manager WHO Country Office for India 28 October 2014 Polio Eradication in India Dr Sunil Bahl Deputy Project Manager WHO Country Office for India 28 October 2014 History of Polio in India Number of Cases 200,000 200,000 OPV Introduced in RI - 1978 150,000

More information

POLIO ERADICATION AND POST-CERTIFICATION STRATEGY

POLIO ERADICATION AND POST-CERTIFICATION STRATEGY POLIO ERADICATION AND POST-CERTIFICATION STRATEGY PRE-BOARD MEETING 5 June 2018, Geneva Reach every child www.gavi.org Agenda Topic Presenter 1. Polio eradication update WHO 10 minutes 2. IPV supply, demand

More information

Targeted Diseases and Immunization. Strategic plan

Targeted Diseases and Immunization. Strategic plan Targeted Diseases and Immunization Strategic plan 2008-2013 Communicable Diseases Unit WHO Regional Office for Europe Mission To provide technical support to WHO European Region Member States to ensure

More information

C o n t e n t s. > Immunizations 4. > Diphtheria 6. > Pertussis 7. > Tetanus 8. > Polio 9. > Measles 10. > Tuberculosis 11.

C o n t e n t s. > Immunizations 4. > Diphtheria 6. > Pertussis 7. > Tetanus 8. > Polio 9. > Measles 10. > Tuberculosis 11. C o n t e n t s > Immunizations 4 > Diphtheria 6 > Pertussis 7 > Tetanus 8 > Polio 9 > Measles 1 > Tuberculosis 11 > Hepatitis B 12 > Rubella and CRS 13 > Haemophius Influenza B 14 I m m u n i z a t i

More information

AIDA M. SALONGA, MD, FPNA, FCNSP CHAIR, AFP EXPERT PANEL, DOH MEMBER, REGIONAL CERTIFICATION COMMITTEE, WHO

AIDA M. SALONGA, MD, FPNA, FCNSP CHAIR, AFP EXPERT PANEL, DOH MEMBER, REGIONAL CERTIFICATION COMMITTEE, WHO POLIO FAQs on ENDGAME Tuberculosis AIDA M. SALONGA, MD, FPNA, FCNSP CHAIR, AFP EXPERT PANEL, DOH MEMBER, REGIONAL CERTIFICATION COMMITTEE, WHO OBJECTIVES Brief history of poliomyelitis Polio eradication:

More information

Highlighting in the WHO European Region: Summary. No. 21(February 2012)

Highlighting in the WHO European Region: Summary. No. 21(February 2012) No. 21(February 2012) Issue 15, April 2011 A monthly publication on vaccine preventable diseases and immunization data and analysis Highlighting in the WHO European Region: Update on measles in the European

More information

Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation

Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation Syrian Programme Refugees Advice on assessment of immunisation status and recommendations for additional immunisation Background Information Immunisation services in Syria Syria had good immunisation services,

More information

SEA-Immun-105 Distribution: General. WHO South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG)

SEA-Immun-105 Distribution: General. WHO South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) SEA-Immun-105 Distribution: General WHO South-East Asia Regional Immunization Technical Advisory Group (SEAR-ITAG) Report of the Seventh Meeting of SEAR-ITAG New Delhi, India, 7 10 June 2016 World Health

More information

IEAG Findings 5-6 December 2005

IEAG Findings 5-6 December 2005 IEAG Findings 5-6 December 005 Surveillance Quality Surveillance Indicators India 005* 5.47 8% Less than 60% 60% to 69% 70% to 79% 80% and above No AFP case * data as on 6th November 005 AFP cases India

More information

VPD in Mediterranean Basin and Black Sea: the Polio case

VPD in Mediterranean Basin and Black Sea: the Polio case Screening practices for infectious diseases among newly arrived migrants and Vaccine Preventable Disease (VPD): strategies and coverage ISS 29 MAY 2015 VPD in Mediterranean Basin and Black Sea: the Polio

More information

Draft Programme (05 May 2016)

Draft Programme (05 May 2016) Innovations in sustainable Draft Programme (05 May 2016) Draft 7 th Meeting of the South-East Asia Region Immunization Technical Advisory Group (SEAR ITAG) 6-10 June 2016, New Delhi (India) Day 1, Monday,

More information

Ministry of Health Viet Nam

Ministry of Health Viet Nam Ministry of Health Viet Nam National Expanded Program on Immunization Comprehensive Multi-Year Plan cmyp for Extended Program on Immunization 2016-2020 Ha Noi, August 2015 Contents Acronyms... 1 Executive

More information

Current National Immunisation Schedule Dr Brenda Corcoran National Immunisation Office.

Current National Immunisation Schedule Dr Brenda Corcoran National Immunisation Office. Current National Immunisation Schedule 2012 Dr Brenda Corcoran National Immunisation Office Objectives To outline immunisation schedules in Ireland Primary childhood schedule Vaccine uptake rates School

More information

Ethics Perspective of Immunisation Programs

Ethics Perspective of Immunisation Programs Ethics Perspective of Immunisation Programs with special reference to Herd Effect T Jacob John Vellore, India Annecy 26 October 2010 Defining Herd immunity and Herd effect. Between participants and nonparticipants

More information

EPI and VPD Surveillance Review and Post-Introduction Evaluation of Hib (Pentavalent) Vaccine

EPI and VPD Surveillance Review and Post-Introduction Evaluation of Hib (Pentavalent) Vaccine EPI and VPD Surveillance Review and Post-Introduction Evaluation of Hib (Pentavalent) Vaccine Report of the Mission Bangladesh, 15-25 March 2012 Regional Office for South-East Asia SEA-Immun-67 Distribution:

More information

Global Health Policy: Vaccines

Global Health Policy: Vaccines Global Health Policy: Vaccines Edwin J. Asturias Senior Investigator Colorado School of Public Health Department of Pediatrics Children s Hospital Colorado UNIVERSITY OF COLORADO COLORADO STATE UNIVERSITY

More information

UNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013

UNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013 UNICEF Procurement Advancements DCVMN Annual Meeting Hanoi, Vietnam October 2013 Presentation overview Scope of UNICEF procurement Overview of UNICEF procurement Vaccine market updates UNICEF procures

More information

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020.

Healthy People 2020 objectives were released in 2010, with a 10-year horizon to achieve the goals by 2020. Appendix 1: Healthy People 2020 Immunization-related Objectives Healthy People provides science-based, 10-year national objectives for improving the health of all Americans. For three decades, Healthy

More information

VII THE CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE 7. 7

VII THE CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE 7. 7 VII THE CHILDHOOD IMMUNISATION PROGRAMME IN SINGAPORE IMMUNISATION PROGRAMME IN 2002 7. 7 The childhood immunisation programme in Singapore offers vaccination against tuberculosis, hepatitis B, diphtheria,

More information

Towards the Achievement of GHSA 2024 s Overarching Targets

Towards the Achievement of GHSA 2024 s Overarching Targets 정보화파트업무계획 [GHSA] Immunization Towards the Achievement of GHSA 2024 s Overarching Targets 2016년추진업무및 2017년업무계획 ( 사업관리 ) 7 th November 2018 Korea Centers for Disease Control and Prevention I. Overview Contents

More information

CHILDHOOD VACCINATION

CHILDHOOD VACCINATION EPI (3) Age of Child How and Where is it given? CHILDHOOD VACCINATION Nicolette du Plessis Block 10 28/02/2012 10 weeks DTaP-IPV/Hib (2) Diphtheria, Tetanus, Acellular pertussis, Inactivated polio vaccine,

More information

This document was published by: The National Department of Health. Editorial team: Provincial EPI Team National EPI Team Dr NJ Ngcobo

This document was published by: The National Department of Health. Editorial team: Provincial EPI Team National EPI Team Dr NJ Ngcobo REVISED : OCTOBER 2010 This document was published by: The National Department of Health Editorial team: Provincial EPI Team National EPI Team Dr NJ Ngcobo Copies may be obtained from: The National Department

More information

Global Polio Eradication & Endgame Strategy. December 2015

Global Polio Eradication & Endgame Strategy. December 2015 Global Polio Eradication & Endgame Strategy December 2015 Poliovirus detection & interruption OPV withdrawal, IPV introduction, RI strengthening Containment & Global Certification Legacy Planning Polio

More information

Why still Polio Donato Greco ECDC polio consultant 14 April 2016

Why still Polio Donato Greco ECDC polio consultant 14 April 2016 Why still Polio Donato Greco ECDC polio consultant 14 April 2016 A medical student with the last texbook on Communicable diseases! Where there is no chapter on Poliomielitis!!! What can I say o Background

More information

CPT 2016 Code Changes

CPT 2016 Code Changes CPT 2016 Code Changes Code Changes - Medicine New CPT 2016 New Codes Code Description 69209 Removal impacted cerumen using irrigation/lavage, unilateral 90620 Meningococcal recombinant protein and outer

More information

WHO/UNICEF Review of National Immunization Coverage India

WHO/UNICEF Review of National Immunization Coverage India WHO/UNICEF Review of National Immunization Coverage 1980-2002 India October, 2003 India Estimates, 1980-2002 80 66 68 73 73 60 40 30 20 10 0 1980 19 1982 1983 1984 1985 1986 1987 1988 1989 19 1991 1992

More information

Measles and Rubella Global Update SAGE 19 October 2017

Measles and Rubella Global Update SAGE 19 October 2017 Measles and Rubella Global Update SAGE 19 October 2017 Alya Dabbagh WHO HQ, IVB/EPI Global update Overview Regional progress and challenges M&RI Midterm Review updates Economics of measles and rubella

More information

Global Report to SAGE. Fulfillment of previous recommendations & progress highlights

Global Report to SAGE. Fulfillment of previous recommendations & progress highlights Global Report to SAGE Fulfillment of previous recommendations & progress highlights SAGE Meeting, 8-10 November 2012 J.M. Okwo-Bele, WHO Outline 1 2 3 4 Global progress Regional updates- RTAGs recommendations

More information

HOA Outbreak Response assessment. Kenya 8 th to 12 th June 2015

HOA Outbreak Response assessment. Kenya 8 th to 12 th June 2015 HOA Outbreak Response assessment Kenya 8 th to 12 th June 2015 Subject areas of assessment Implementation of recommendation from previous assessment Quality of outbreak response AFP surveillance sensitivity

More information

OF MEASLES ELIMINATION

OF MEASLES ELIMINATION GUIDELINES ON VERIFICATION OF MEASLES ELIMINATION IN THE WESTERN PACIFIC REGION 2013 GUIDELINES ON VERIFICATION OF MEASLES ELIMINATION IN THE WESTERN PACIFIC REGION WHO Library Cataloguing-in-Publication

More information

Global and Regional update on Polio Eradication Activities. Kenya Paediatric Association Pride Inn, Mombasa April 26, 2018

Global and Regional update on Polio Eradication Activities. Kenya Paediatric Association Pride Inn, Mombasa April 26, 2018 Global and Regional update on Polio Eradication Activities Kenya Paediatric Association Pride Inn, Mombasa April 26, 2018 Presentation Outline 1. Background information 2. Poliovirus detection & interruption

More information

GLOBAL IMMUNIZATION COVERAGE IN 2016

GLOBAL IMMUNIZATION COVERAGE IN 2016 NATIONAL IMMUNIZATION COVERAGE SCORECARDS ESTIMATES FOR 2016 GLOBAL IMMUNIZATION COVERAGE IN 2016 In May 2012, the Sixty-fifth World Health Assembly endorsed the Global Vaccine Action Plan (GVAP) for the

More information

1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector

1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast ( ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector 1. Executive Summary 2. Worldwide Pediatric Vaccines Market and Forecast (2006 ) 3. Worldwide Pediatric Vaccines Market Share & Forecast (Sector wise) (2005 ) 4. Worldwide Pediatric Vaccines Market Share

More information

New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines

New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines New Jersey Department of Health Vaccine Preventable Disease Program Childhood and Adolescent Recommended Vaccines Antigens Vaccine Approved Age Daptacel Diphtheria, Tetanus, and acellular Pertussis (DTaP)

More information

VACCINE DIALOGUE AIDC 2017

VACCINE DIALOGUE AIDC 2017 VACCINE DIALOGUE AIDC 2017 Idea is Not to discuss about each vaccine Discuss about when to use- clinical situations Allaying the fears ADULT VACCINES Question What are the current CDC recommendations on

More information

Table 1. Measles case classification and incidence by country and area, WHO Western Pacific Region,

Table 1. Measles case classification and incidence by country and area, WHO Western Pacific Region, Volume 7 Issue 5 May 2013 ISSN 1814 3601 Table 1. case classification and by country and area, WHO Western Pacific Region, 2008 2013 1 confirmed 2 2 009 per confirmed 2 2 010 2 011 2 012 2013 1 Confirmed

More information

Public Statement: Medical Policy. Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many. Document: ARB0454:04.

Public Statement: Medical Policy. Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many. Document: ARB0454:04. ARBenefits Approval: 01/01/2012 Effective Date: 01/01/2012 Revision Date: 03/24/2014 Code(s): Many Medical Policy Title: Immunization Coverage Document: ARB0454:04 Administered by: Public Statement: 1.

More information

Global landscape analysis and literature review of 2 nd Year of Life immunization platform

Global landscape analysis and literature review of 2 nd Year of Life immunization platform Global landscape analysis and literature review of 2 nd Year of Life immunization platform Global Vaccine and Immunization Research Forum 15-17 March 2016 Johannesburg, South Africa Imran Mirza; Celina

More information

Global Immunization Vision and Strategies (GIVS) Vaccine Tender , Pretender Meeting, Copenhagen December 2008

Global Immunization Vision and Strategies (GIVS) Vaccine Tender , Pretender Meeting, Copenhagen December 2008 Global Immunization Vision and Strategies (GIVS) 2006-2015 Vaccine Tender 2010-2012, Pretender Meeting, Copenhagen 10-11 December 2008 Dr Ahmed Magan & Dr Osman David Mansoor Programme Division UNICEF

More information

Adolescent vaccination strategies

Adolescent vaccination strategies Adolescent vaccination strategies Gregory Hussey Vaccines for Africa Initiative Institute of Infectious Diseases & Molecular Medicine University of Cape Town www.vacfa.uct.ac.za gregory.hussey@uct.ac.za

More information

Meeting Report June 2018 Manila, Philippines

Meeting Report June 2018 Manila, Philippines Meeting Report 27TH MEETING OF THE TECHNICAL ADVISORY GROUP ON IMMUNIZATION AND VACCINE-PREVENTABLE DISEASES IN THE WESTERN PACIFIC REGION 19 22 June 2018 Manila, Philippines WORLD HEALTH ORGANIZATION

More information

RECOMMENDED IMMUNIZATIONS

RECOMMENDED IMMUNIZATIONS Recommended Immunization Schedule for Persons Aged 0 Through 6 Years United States 2010 1 2 4 6 12 15 18 19 23 2 3 4 6 Vaccine Age Birth month months months months months months months months years years

More information

WHITE PAPER. A Summary of Global Immunization Coverage through David W Brown, Anthony H Burton, Marta Gacic-Dobo (alphabetical order)

WHITE PAPER. A Summary of Global Immunization Coverage through David W Brown, Anthony H Burton, Marta Gacic-Dobo (alphabetical order) WHITE PAPER A Summary of Global Immunization Coverage through 2013 David W Brown, Anthony H Burton, Marta Gacic-Dobo (alphabetical order) for the WHO and UNICEF working group for monitoring national immunization

More information

Pertussis. (Whole-cell pertussis vaccines) must not be frozen, but stored at 2 8 C. All wp vaccines have an expiry date of months.

Pertussis. (Whole-cell pertussis vaccines) must not be frozen, but stored at 2 8 C. All wp vaccines have an expiry date of months. Program Management 61_5 The wp vaccines have a considerably lower price than ap vaccines and, where resources are limited and the vaccine is well accepted by the local population, wp vaccine remains the

More information

VPD Update for Week 1, 2018 Data as of 8 January 2018 Immunization and Vaccine Development (IVD) SEARO

VPD Update for Week 1, 2018 Data as of 8 January 2018 Immunization and Vaccine Development (IVD) SEARO VPD Update for Week 1, 2018 Data as of 8 January 2018 Immunization and Vaccine Development (IVD) SEARO Protecting People from Vaccine Preventable Diseases Last wild poliovirus cases confirmed by type,

More information

Preventing Vaccine-Preventable Diseases in HIV-Infected Children and Adults

Preventing Vaccine-Preventable Diseases in HIV-Infected Children and Adults Preventing Vaccine-Preventable Diseases in HIV-Infected Children and Adults 1. Objective The objectives of this chapter are to underline the role of vaccination in reducing morbidity and mortality in HIV

More information

Impact of Immunization on Under 5 Mortality

Impact of Immunization on Under 5 Mortality Annals of Community Health (AoCH) pissn 2347-5455 eissn 2347-5714 An Indexed (Index Medicus, DOAJ and More), Peer Reviewed, Quarterly, International Journal focusing exclusively on Community Medicine and

More information

Poliomyelitis: successful and critical issues in the eradication process

Poliomyelitis: successful and critical issues in the eradication process Vaccine Preventable Diseases in the Mediterranean Basin and Black Sea: immunization strategies and coverage in the general population and the newly arrived migrants the ProVacMed project Poliomyelitis:

More information

ANNUAL HEALTH SCREENINGS AND IMMUNIZATIONS GUIDE MEN WOMEN ALL ADULTS CHILDREN

ANNUAL HEALTH SCREENINGS AND IMMUNIZATIONS GUIDE MEN WOMEN ALL ADULTS CHILDREN AND IMMUNIZATIONS GUIDE MEN WOMEN ALL ADULTS CHILDREN MEN PROSTATE CANCER Testicular exam Age 18+ PSA test Ages 50-75, based on risk WOMEN BREAST CANCER Self breast exam Monthly Clinical breast exam Annually

More information

Objective 2 Strengthening Routine Immunization, IPV introduction and the topv-bopv switch

Objective 2 Strengthening Routine Immunization, IPV introduction and the topv-bopv switch Objective 2 Strengthening Routine Immunization, IPV introduction and the topv-bopv switch Polio Partners Group meeting Geneva 8 December 2014 Michel Zaffran Coordinator, WHO/EPI, IMG Co-chair On behalf

More information

Recommended Childhood Immunization Schedu...ates, January - December 2000, NP Central

Recommended Childhood Immunization Schedu...ates, January - December 2000, NP Central Recommended Childhood Immunization Schedule United States, January - December 2000 Vaccines 1 are listed under routinely recommended ages. Solid-colored bars indicate range of recommended ages for immunization.

More information

Cyprus Experience. Dr. Elena Papamichael Ministry of Health

Cyprus Experience. Dr. Elena Papamichael Ministry of Health Cyprus Experience Dr. Elena Papamichael Ministry of Health Cyprus became independent on1960. On 1974, Turkish troops invaded in the island disturbing the willing for peaceful living. Since then, Turkey

More information

Mongolia s Comprehensive Multi-Year Plan for Immunization ( )

Mongolia s Comprehensive Multi-Year Plan for Immunization ( ) Draft of Third Edition (4 May 2007) Mongolia s Comprehensive Multi-Year Plan for Immunization (2007-2012) Khuvsgul Bayan-Ulgii Uv Khovd Zavkha Arkhangai Seleng Bulga Darkhan- Orkhon! Tu Khentii Dornod

More information

宮村参考人提出資料 資料 2-2

宮村参考人提出資料 資料 2-2 宮村参考人提出資料 資料 - Highlights of New Wild Poliovirus and cvdpv Positives Reported Globally this Week WPV cvdpv AFP other AFP other Afghanistan 5 Pakistan 3 Nigeria Location: state/province/governorate Kunar

More information

Update on Transition: the case of Honduras. Minister Dra Yolani Batres AMRO/EURO Gavi Constituency Representative Geneva June 2016

Update on Transition: the case of Honduras. Minister Dra Yolani Batres AMRO/EURO Gavi Constituency Representative Geneva June 2016 Update on Transition: the case of Honduras Minister Dra Yolani Batres AMRO/EURO Gavi Constituency Representative Geneva June 2016 GAVI Support for Honduras Content Honduras EPI Situation 2011-2016 Vaccination

More information

Joint National/International Review of Acute Flaccid Paralysis (AFP) Surveillance Nepal

Joint National/International Review of Acute Flaccid Paralysis (AFP) Surveillance Nepal SEA Polio 44 Distribution: Limited Joint National/International Review of Acute Flaccid Paralysis (AFP) Surveillance Nepal 25 March 6 April 2006 and 6-12 August 2006 World Health Organization This document

More information

WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC

WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR THE WESTERN PACIFIC REPORT SIXTEENTH MEETING OF THE TECHNICAL ADVISORY GROUP ON IMMUNIZATION AND VACCINE PREVENTABLE DISEASES IN THE WESTERN PACIFIC REGION

More information

Back to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office

Back to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office Back to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office SAGE, Geneva 27 October 2009 Rebecca Martin Targeted Diseases and

More information

3. CONCLUSIONS AND RECOMMENDATIONS

3. CONCLUSIONS AND RECOMMENDATIONS 3. CONCLUSIONS AND RECOMMENDATIONS 3.1 Polio Endgame Strategy Conclusions 1. The TAG welcomes the RCC conclusion that Western Pacific Region maintains its polio-free status, and commends China for the

More information

Thank you for joining, the M&RI webinar will begin shortly

Thank you for joining, the M&RI webinar will begin shortly Thank you for joining, the M&RI webinar will begin shortly Please mute your phone or microphone Please do not place the call on hold If you have difficulty with the quality of the connection then here

More information

UIP FACT SHEET. Socio - demographic profile PRL. Infant Mortality Rate

UIP FACT SHEET. Socio - demographic profile PRL. Infant Mortality Rate UIP FACT SHEET WEST BENGAL Census 1 Total Population 8,176,197 Population--6yr 11,414,222 Literacy Rate 68.6 Sex Ratio 934 Sex Ratio -6 yr 96 Socio - demographic profile Census 11 91,347,736 1,112,599

More information

Status of Outbreak Vulnerable Countries

Status of Outbreak Vulnerable Countries Status of Outbreak Vulnerable Countries Hamid Jafari, WHO Robert Linkins, CDC Independent Monitoring Board Meeting 7-8 May, 2013 Outline Non-Endemic Vulnerable & At-Risk Countries Recently infected countries

More information

CDC ASSESSMENT OF RISKS TO THE GLOBAL POLIO ERADICATION INITIATIVE (GPEI) STRATEGIC PLAN

CDC ASSESSMENT OF RISKS TO THE GLOBAL POLIO ERADICATION INITIATIVE (GPEI) STRATEGIC PLAN CDC ASSESSMENT OF RISKS TO THE GLOBAL POLIO ERADICATION INITIATIVE (GPEI) STRATEGIC PLAN 2010-2012 14 Sept-10 2010 First and Second Quarters (January June) Geographic distribution of wild poliovirus (WPV)

More information

Benefit Interpretation

Benefit Interpretation Benefit Interpretation Subject: Part B vs. Part D Vaccines Issue Number: BI-039 Applies to: Medicare Advantage Effective Date: May 1, 2017 Attachments: Part B Vaccines Diagnosis Code Limits Table of Contents

More information